Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Common Equity (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Common Equity for 6 consecutive years, with $308.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 25.66% to $308.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $308.2 million, a 25.66% increase, with the full-year FY2025 number at $308.2 million, up 25.66% from a year prior.
  • Common Equity was $308.2 million for Q4 2025 at GeneDx Holdings, up from $292.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $637.3 million in Q2 2022 to a low of -$566.5 million in Q2 2021.
  • A 5-year average of $228.3 million and a median of $267.3 million in 2025 define the central range for Common Equity.
  • Biggest YoY gain for Common Equity was 291.33% in 2021; the steepest drop was 283.41% in 2021.
  • GeneDx Holdings' Common Equity stood at $388.1 million in 2021, then tumbled by 34.63% to $253.7 million in 2022, then fell by 10.13% to $228.0 million in 2023, then increased by 7.56% to $245.2 million in 2024, then rose by 25.66% to $308.2 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Common Equity are $308.2 million (Q4 2025), $292.3 million (Q3 2025), and $277.1 million (Q2 2025).